Replimune Group (NASDAQ:REPL) Issues Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Replimune Group (NASDAQ:REPL) announced its quarterly earnings data on Wednesday. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09), Zacks reports.

Replimune Group Stock Performance

NASDAQ REPL traded down $0.23 during trading hours on Thursday, hitting $13.56. The company had a trading volume of 44,777 shares, compared to its average volume of 761,002. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The firm has a market cap of $927.50 million, a P/E ratio of -4.46 and a beta of 1.30. Replimune Group has a fifty-two week low of $4.92 and a fifty-two week high of $17.00. The business has a fifty day simple moving average of $12.49 and a 200-day simple moving average of $11.67.

Insider Activity

In other news, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. This represents a 4.72 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on REPL shares. Jefferies Financial Group lifted their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. BMO Capital Markets lifted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright boosted their price target on Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Buy” and a consensus target price of $19.29.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.